Re Agreement

PROTEOME SCIENCES plc

 

28th September 2006

 

Stroke Licence Agreement

 

Proteome Sciences plc ("Proteome Sciences") is pleased to announce a research
licence agreement with a further leading global diagnostics company in order
for that company to evaluate Proteome Sciences' biomarkers for the detection,
diagnosis and monitoring of stroke. The biomarkers were discovered and
validated using a combination of different proteomic approaches available
through Proteome Sciences' proprietary ProteoSHOP® platform.

 

Annually, 15 million people worldwide suffer a stroke. Of these, 5.5 million
die and another 5 million are left permanently disabled, placing a burden on
family and community.

 

In the United States about 750,000 people suffer a new or recurrent stroke each
year. Nearly 160,000 of these people die, making stroke the third leading cause
of death. 

 

About 5.5 million U.S. stroke survivors are alive today, many of them with
permanent stroke-related disabilities. The estimated direct and indirect cost
of stroke for 2006 is $57.9 billion.

 

No financial details were disclosed.

 

 

Christopher Pearce, CEO of Proteome Sciences, said

 

"This is further endorsement of the important role that our stroke biomarkers
are playing to generate new breeds of diagnostic products and the power of the
ProteoSHOP® toolbox which has been successfully applied across a range of
different human diseases including cancer and neurodegeneration.

 

We are delighted to have signed a fourth licence in stroke with another global
diagnostics company and we look forward to seeing our biomarkers being
incorporated on their diagnostic platforms."

 

-  Ends  -


Notes to editors:

 

Proteome Sciences plc

 

Proteome Sciences, a global leader in applied proteomics, uses high sensitivity
proprietary technologies to detect differentially expressed proteins in
diseases. The protein biomarkers discovered in body fluids or tissues are
validated, developed and commercialised as diagnostic, prognostic or
therapeutic products through strategic alliances and out-licensing.

Through its unique ProteoSHOP® toolbox, Proteome Sciences provides high
sensitivity/high throughput proteomics solutions, including traditional two
dimensional gel-based electrophoresis (2DE) and proprietary gel-free protein
sequence tag technologies (PST®, qPST™& TMT®), to major pharma, biotechnology
and diagnostic companies, to discover and exploit protein biomarkers.
Sensitizer® chemical mass tags have been developed separately as a series of
stand-alone reagents.

For further information please visit www.proteomics.com.

 

 

 

Enquiries:

 

Proteome Sciences plc

 

Dr. Ian Pike, Business Development Director

Email: [e-mail]

 

Christopher Pearce, Chief Executive Officer

Email: [e-mail]

 

Tel: [phone]

 

 

Public Relations for Proteome Sciences

 

IKON Associates

 

Adrian Shaw                                 

Tel:      [phone]

Mobile: [phone]

Email:      [e-mail]